A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon

Johdi, 2020, Colorectal Cancer Immunotherapy: Options and Strategies, Front. Immunol., 11, 1624, 10.3389/fimmu.2020.01624 Dunn, 2006, Interferons, immunity and cancer immunoediting, Nat. Rev. Immunol., 6, 836, 10.1038/nri1961 Takaoka, 2003, Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence, Nature, 424, 516, 10.1038/nature01850 Silverman, 2003, Implications for RNase L in prostate cancer biology, Biochemistry, 42, 1805, 10.1021/bi027147i Hanada, 2006, IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice, J. Exp. Med., 203, 1391, 10.1084/jem.20060436 Lin, 2018, Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression, J. Clin. Invest., 128, 1708, 10.1172/JCI120803 Diskin, 2020, PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer, Nat. Immunol., 21, 442, 10.1038/s41590-020-0620-x Campesato, 2020, Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine, Nat. Commun., 11, 4011, 10.1038/s41467-020-17750-z Zhuang, 2019, Genome-Wide CRISPR Screen Reveals Cancer Cell Resistance to NK Cells Induced by NK-Derived IFN-γ, Front. Immunol., 10, 2879, 10.3389/fimmu.2019.02879 Liau, 2018, The molecular basis of JAK/STAT inhibition by SOCS1, Nat. Commun., 9, 1558, 10.1038/s41467-018-04013-1 Di Franco, 2017, Role of Type I and II Interferons in Colorectal Cancer and Melanoma, Front. Immunol., 8, 878, 10.3389/fimmu.2017.00878 Bogdan, 2004, The role of type I interferons in non-viral infections, Immunol. Rev., 202, 33, 10.1111/j.0105-2896.2004.00207.x Xu, 2019, Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy, J. Clin. Invest., 129, 4316, 10.1172/JCI129317 Wang, 2015, Deficiency of interferon-gamma or its receptor promotes colorectal cancer development, J. Interferon Cytokine Res., 35, 273, 10.1089/jir.2014.0132 Chawla-Sarkar, 2003, Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis, Apoptosis., 8, 237, 10.1023/A:1023668705040 Thapa, 2011, NF-kappaB protects cells from gamma interferon-induced RIP1-dependent necroptosis, Mol. Cell. Biol., 31, 2934, 10.1128/MCB.05445-11 Du, 2022, IFNγ signaling integrity in colorectal cancer immunity and immunotherapy, Cell. Mol. Immunol., 19, 23, 10.1038/s41423-021-00735-3 Kemeny, 1990, Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity, Cancer, 66, 2470, 10.1002/1097-0142(19901215)66:12<2470::AID-CNCR2820661205>3.0.CO;2-Y Chaurasiya, 2020, Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges, Cancers (Basel), 12, 10.3390/cancers12061699 Castro, 2018, Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion, Front. Immunol., 9, 847, 10.3389/fimmu.2018.00847 Li, 2010, Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy, Cancer Gene Ther., 17, 550, 10.1038/cgt.2010.10 Shi, 2020, Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling, J. Exp. Med., 217, 10.1084/jem.20192282 Jobin, 2013, Colorectal cancer: looking for answers in the microbiota, Cancer Discov., 3, 384, 10.1158/2159-8290.CD-13-0042 Tlaskalova-Hogenova, 2014, Microbiome and colorectal carcinoma: insights from germ-free and conventional animal models, Cancer J., 20, 217, 10.1097/PPO.0000000000000052 Tsai, 2019, Probiotics, prebiotics and amelioration of diseases, J. Biomed. Sci., 26, 3, 10.1186/s12929-018-0493-6 den Besten, 2013, The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism, J. Lipid Res., 54, 2325, 10.1194/jlr.R036012 Natividad, 2013, Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications, Pharmacol. Res., 69, 42, 10.1016/j.phrs.2012.10.007 Bäumler, 2016, Interactions between the microbiota and pathogenic bacteria in the gut, Nature, 535, 85, 10.1038/nature18849 Gensollen, 2016, How colonization by microbiota in early life shapes the immune system, Science, 352, 539, 10.1126/science.aad9378 Hashemi Goradel, 2019, Fusobacterium nucleatum and colorectal cancer: A mechanistic overview, J. Cell. Physiol., 234, 2337, 10.1002/jcp.27250 Hayashi, 2013, A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice, Cell Host Microbe, 13, 711, 10.1016/j.chom.2013.05.013 Chen, 2022, Fusobacterium nucleatum reduces METTL3-mediated m(6)A modification and contributes to colorectal cancer metastasis, Nat. Commun., 13, 1248, 10.1038/s41467-022-28913-5 de Almeida, 2018, The controversial role of Enterococcus faecalis in colorectal cancer, Therap. Adv. Gastroenterol., 11, 10.1177/1756284818783606 Vizcaino, 2015, The colibactin warhead crosslinks DNA, Nat. Chem., 7, 411, 10.1038/nchem.2221 Chung, 2018, Bacteroides fragilis Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells, Cell Host Microbe, 23, 421, 10.1016/j.chom.2018.02.004 Boleij, 2015, The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients, Clin. Infect. Dis., 60, 208, 10.1093/cid/ciu787 Belkaid, 2014, Role of the microbiota in immunity and inflammation, Cell, 157, 121, 10.1016/j.cell.2014.03.011 Duijster, 2021, Association between Salmonella infection and colon cancer: a nationwide registry-based cohort study, Epidemiol. Infect., 149, e56, 10.1017/S0950268821000285 Lara-Tejero, 2000, A bacterial toxin that controls cell cycle progression as a deoxyribonuclease I-like protein, Science, 290, 354, 10.1126/science.290.5490.354 Arthur, 2012, Intestinal inflammation targets cancer-inducing activity of the microbiota, Science, 338, 120, 10.1126/science.1224820 Semin, 2021, Interplay Between Microbiota, Toll-Like Receptors and Cytokines for the Maintenance of Epithelial Barrier Integrity, Front. Med., 8, 10.3389/fmed.2021.644333 Duan, 2022, Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity, Front. Immunol., 13, 10.3389/fimmu.2022.812774 Lasry, 2016, Inflammatory networks underlying colorectal cancer, Nat. Immunol., 17, 230, 10.1038/ni.3384 Malik, 2018, SYK-CARD9 Signaling Axis Promotes Gut Fungi-Mediated Inflammasome Activation to Restrict Colitis and Colon Cancer, Immunity, 49, 515, 10.1016/j.immuni.2018.08.024 Wiechers, 2021, The microbiota is dispensable for the early stages of peripheral regulatory T cell induction within mesenteric lymph nodes, Cell. Mol. Immunol., 18, 1211, 10.1038/s41423-021-00647-2 Saraiva, 2010, The regulation of IL-10 production by immune cells, Nat. Rev. Immunol., 10, 170, 10.1038/nri2711 Huber, 2004, Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells, J. Immunol., 173, 6526, 10.4049/jimmunol.173.11.6526 De Simone, 2013, Role of T(H)17 cytokines in the control of colorectal cancer, Oncoimmunology, 2, 10.4161/onci.26617 Lee, 2020, Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease, Cell, 183, 2036, 10.1016/j.cell.2020.12.008 Ghoreschi, 2010, Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling, Nature, 467, 967, 10.1038/nature09447 Sivan, 2015, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy, Science, 350, 1084, 10.1126/science.aac4255 Vétizou, 2015, Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota, Science, 350, 1079, 10.1126/science.aad1329 Daillère, 2016, Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects, Immunity, 45, 931, 10.1016/j.immuni.2016.09.009 Tanoue, 2019, A defined commensal consortium elicits CD8 T cells and anti-cancer immunity, Nature, 565, 600, 10.1038/s41586-019-0878-z Bai, 2021, Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment, J. Clin. Lab. Anal., 35 Siegel, 2017, Colorectal cancer statistics, 2017, CA. Cancer J. Clin., 67, 177, 10.3322/caac.21395 Ganesh, 2019, Immunotherapy in colorectal cancer: rationale, challenges and potential, Nat. Rev. Gastroenterol. Hepatol., 16, 361, 10.1038/s41575-019-0126-x Cui, 2021, The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses, Front. Oncol., 11 Payandeh, 2020, PD-1/PD-L1-dependent immune response in colorectal cancer, J. Cell. Physiol., 235, 5461, 10.1002/jcp.29494 Luddy, 2014, The role of toll-like receptors in colorectal cancer progression: evidence for epithelial to leucocytic transition, Front. Immunol., 5, 429, 10.3389/fimmu.2014.00429 Zmora, 2017, Inflammasomes and intestinal inflammation, Mucosal Immunol., 10, 865, 10.1038/mi.2017.19 Tilg, 2018, The Intestinal Microbiota in Colorectal Cancer, Cancer Cell, 33, 954, 10.1016/j.ccell.2018.03.004 Brennan, 2016, Gut Microbiota, Inflammation, and Colorectal Cancer, Annu. Rev. Microbiol., 70, 395, 10.1146/annurev-micro-102215-095513 Mantovani, 2008, Cancer-related inflammation, Nature, 454, 436, 10.1038/nature07205 Thaiss, 2016, The microbiome and innate immunity, Nature, 535, 65, 10.1038/nature18847 Kostic, 2012, Genomic analysis identifies association of Fusobacterium with colorectal carcinoma, Genome Res., 22, 292, 10.1101/gr.126573.111 Mima, 2015, Fusobacterium nucleatum and T Cells in Colorectal Carcinoma, JAMA Oncol., 1, 653, 10.1001/jamaoncol.2015.1377 Brennan, 2019, Fusobacterium nucleatum - symbiont, opportunist and oncobacterium, Nat. Rev. Microbiol., 17, 156, 10.1038/s41579-018-0129-6 Yang, 2018, A common antimicrobial additive increases colonic inflammation and colitis-associated colon tumorigenesis in mice, Sci. Transl. Med., 10, 10.1126/scitranslmed.aan4116 Abed, 2016, Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc, Cell Host Microbe, 20, 215, 10.1016/j.chom.2016.07.006 Sears, 2011, Perspective: alpha-bugs, their microbial partners, and the link to colon cancer, J. Infect. Dis., 203, 306, 10.1093/jinfdis/jiq061 Boleij, 2011, Clinical Importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis, Clin. Infect. Dis., 53, 870, 10.1093/cid/cir609 Litvak, 2018, Colonocyte metabolism shapes the gut microbiota, Science, 362, 10.1126/science.aat9076 Xing, 2022, Interaction between microbiota and immunity and its implication in colorectal cancer, Front. Immunol., 13, 10.3389/fimmu.2022.963819 Obiso, 1995, Proteolytic activity of the Bacteroides fragilis enterotoxin causes fluid secretion and intestinal damage in vivo, Infect. Immun., 63, 3820, 10.1128/iai.63.10.3820-3826.1995 Athan, 2019, Silent but deadly: patients with enterococcal bacteraemia should be assessed for colorectal neoplasia, Med. J. Aust., 210, 86, 10.5694/mja2.12027 Chang, 2014, The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition, Proc. Natl. Acad. Sci. USA, 111, 2247, 10.1073/pnas.1322269111 Wang, 2020, Sodium Butyrate Selectively Kills Cancer Cells and Inhibits Migration in Colorectal Cancer by Targeting Thioredoxin-1, Onco. Targets Ther., 13, 4691, 10.2147/OTT.S235575 Nastasi, 2015, The effect of short-chain fatty acids on human monocyte-derived dendritic cells, Sci. Rep., 5, 10.1038/srep16148 Ji, 2016, Microbial metabolite butyrate facilitates M2 macrophage polarization and function, Sci. Rep., 6, 10.1038/srep24838 Smith, 2013, The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis, Science, 341, 569, 10.1126/science.1241165 Bullman, 2017, Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer, Science, 358, 1443, 10.1126/science.aal5240 Geller, 2017, Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine, Science, 357, 1156, 10.1126/science.aah5043 Gopalakrishnan, 2018, The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy, Cancer Cell, 33, 570, 10.1016/j.ccell.2018.03.015 Kuchtey, 2005, Enhancement of dendritic cell antigen cross-presentation by CpG DNA involves type I IFN and stabilization of class I MHC mRNA, J. Immunol., 175, 2244, 10.4049/jimmunol.175.4.2244 Le Bon, 2003, Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon, Nat. Immunol., 4, 1009, 10.1038/ni978 Sethi, 2018, Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response, Gastroenterology, 155, 33, 10.1053/j.gastro.2018.04.001 Schoenborn, 2007, Regulation of interferon-gamma during innate and adaptive immune responses, Adv. Immunol., 96, 41, 10.1016/S0065-2776(07)96002-2 Woznicki, 2020, Human BCL-G regulates secretion of inflammatory chemokines but is dispensable for induction of apoptosis by IFN-γ and TNF-α in intestinal epithelial cells, Cell Death Dis., 11, 68, 10.1038/s41419-020-2263-0 Chang, 2013, Posttranscriptional control of T cell effector function by aerobic glycolysis, Cell, 153, 1239, 10.1016/j.cell.2013.05.016 Kawashima, 2013, Double-stranded RNA of intestinal commensal but not pathogenic bacteria triggers production of protective interferon-β, Immunity, 38, 1187, 10.1016/j.immuni.2013.02.024 Wirusanti, 2022, Microbiota regulation of viral infections through interferon signaling, Trends Microbiol., 30, 778, 10.1016/j.tim.2022.01.007 Erttmann, 2022, The gut microbiota prime systemic antiviral immunity via the cGAS-STING-IFN-I axis, Immunity, 55, 847, 10.1016/j.immuni.2022.04.006 Du, 2022, Activation of cGAS-STING by Lethal Malaria N67C Dictates Immunity and Mortality through Induction of CD11b(+) Ly6C(hi) Proinflammatory Monocytes, Adv. Sci., 9, 10.1002/advs.202103701 Kana, 2021, Immuno-Oncolytic Viruses: Emerging Options in the Treatment of Colorectal Cancer, Mol. Diagn. Ther., 25, 301, 10.1007/s40291-021-00517-7 Kaufman, 2015, Oncolytic viruses: a new class of immunotherapy drugs, Nat. Rev. Drug Discov., 14, 642, 10.1038/nrd4663 Bommareddy, 2018, Integrating oncolytic viruses in combination cancer immunotherapy, Nat. Rev. Immunol., 18, 498, 10.1038/s41577-018-0014-6 Kim, 2020, Vitamin D as a Primer for Oncolytic Viral Therapy in Colon Cancer Models, Int. J. Mol. Sci., 21 Ren, 2022, Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option, Front. Immunol., 13, 10.3389/fimmu.2022.961796 2012, Oncolytic viruses successfully delivered intravenously, Hum. Vaccin. Immunother., 8, 1014 Engeland, 2021, Re: "Oncolytic Measles Virus Encoding Interleukin-12 Mediated Antitumor Activity and Immunologic Control of Colon Cancer In Vivo and Ex Vivo" by Wang et al, Cancer Biother. Radiopharm., 36, 106 He, 2021, Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer, Front. Oncol., 11, 10.3389/fonc.2021.764618 Liu, 2021, [Oncolytic vaccinia virus expressing CD40L (CD40L-VV) inhibits colorectal cancer cell growth and enhances anti-tumor activity of T cells in tumor-bearing mice], Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 37, 602 Carpenter, 2010, Regional liver therapy using oncolytic virus to target hepatic colorectal metastases, Semin. Oncol., 37, 160, 10.1053/j.seminoncol.2010.03.001 Vigil, 2007, Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus, Cancer Res., 67, 8285, 10.1158/0008-5472.CAN-07-1025 Scheubeck, 2019, Starvation-Induced Differential Virotherapy Using an Oncolytic Measles Vaccine Virus, Viruses, 11, 10.3390/v11070614 Garijo, 2014, Experimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells, PLoS One, 9, 10.1371/journal.pone.0102365 Cho, 2010, Down-regulation of HIF-1alpha by oncolytic reovirus infection independently of VHL and p53, Cancer Gene Ther., 17, 365, 10.1038/cgt.2009.84 Babaei, 2020, The synergistic anticancer effects of ReoT3D, CPT-11, and BBI608 on murine colorectal cancer cells, Daru., 28, 555, 10.1007/s40199-020-00361-w Ma, 2012, Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer, Oncol. Rep., 27, 1443 Yuan, 2017, An Oncolytic Adenovirus Expressing SNORD44 and GAS5 Exhibits Antitumor Effect in Colorectal Cancer Cells, Hum. Gene Ther., 28, 690, 10.1089/hum.2017.041 Chia, 2017, Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer, Virology, 505, 162, 10.1016/j.virol.2017.02.011 Rezazadeh, 2022, Comparison of the Effect of Adipose Mesenchymal Stem Cells-Derived Secretome with and without Reovirus in CT26 Cells, Arch. Razi Inst., 77, 615 Tedcastle, 2016, Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth, Mol. Ther., 24, 796, 10.1038/mt.2015.233 Wu, 2019, Oncolytic Vaccinia Virus Expressing Aphrocallistes vastus Lectin as a Cancer Therapeutic Agent, Mar. Drugs, 17, 10.3390/md17060363 Hu, 2021, β-Adrenergic Receptor Inhibitor and Oncolytic Herpesvirus Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects on Colorectal Cancer, Front. Pharmacol., 12, 10.3389/fphar.2021.735278 Arulanandam, 2015, VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection, Cancer Cell, 28, 210, 10.1016/j.ccell.2015.06.009 Li, 2017, An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation, Hum. Gene Ther., 1, 667, 10.1089/hum.2017.033 Tysome, 2009, Combination of anti-angiogenic therapy and virotherapy: arming oncolytic viruses with anti-angiogenic genes, Curr. Opin. Mol. Ther., 11, 664 Lee, 2020, Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer, J. Immunother. Cancer, 8 Heo, 2013, Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer, Nat. Med., 19, 329, 10.1038/nm.3089 Chen, 2021, Identification of in vitro and in vivo oncolytic effect in colorectal cancer cells by Orf virus strain NA1/11, Oncol. Rep., 45, 535, 10.3892/or.2020.7885 Currier, 2013, VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells, Mol. Ther., 21, 1014, 10.1038/mt.2013.39 Yoo, 2007, VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth, Mol. Ther., 15, 295, 10.1038/sj.mt.6300023 Yoo, 2016, A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer, Oncotarget, 7, 16479, 10.18632/oncotarget.7660 Parakrama, 2020, Immune characterization of metastatic colorectal cancer patients post reovirus administration, BMC Cancer, 20, 569, 10.1186/s12885-020-07038-2 Jing, 2009, Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor, Cancer Res., 69, 1459, 10.1158/0008-5472.CAN-08-2628 Liikanen, 2013, Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients, Mol. Ther., 21, 1212, 10.1038/mt.2013.51 Guerrero, 2020, Induction of Cell Death in the Human Acute Lymphoblastic Leukemia Cell Line Reh by Infection with Rotavirus Isolate Wt1-5, Biomedicines, 8, 10.3390/biomedicines8080242 Conrad, 2015, Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice, J. Exp. Clin. Cancer Res., 34, 19, 10.1186/s13046-015-0131-z Liikanen, 2015, Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy, Oncoimmunology, 4, 10.4161/2162402X.2014.989771 Rommelfanger, 2013, The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice, Mol. Ther., 21, 348, 10.1038/mt.2012.204 Deng, 2021, IL-24-Armed Oncolytic Vaccinia Virus Exerts Potent Antitumor Effects via Multiple Pathways in Colorectal Cancer, Oncol. Res., 28, 579, 10.3727/096504020X15942028641011 Nakao, 2020, Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade, Sci. Transl. Med., 12, 10.1126/scitranslmed.aax7992 Choi, 2013, Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity, PLoS One, 8 Kim, 2021, Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1, Gene Ther., 28, 186, 10.1038/s41434-020-00205-x Grossardt, 2013, Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine, Hum. Gene Ther., 24, 644, 10.1089/hum.2012.205 Yan, 2015, Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity, Tumour Biol., 36, 4535, 10.1007/s13277-015-3098-7 Jennings, 2019, Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition, Mol. Ther., 27, 1139, 10.1016/j.ymthe.2019.04.008 Xiao, 2021, Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients, J. Immunol. Res., 2021 Cervera-Carrascon, 2018, TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade, Oncoimmunology, 7, 10.1080/2162402X.2017.1412902 Stephenson, 2012, Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity, Cancer Gene Ther., 19, 238, 10.1038/cgt.2011.81 Sobhanimonfared, 2018, Combination of virotherapy with VSV and tumor vaccination significantly enhances the efficacy of antitumor therapy, Acta Virol., 62, 394, 10.4149/av_2018_407 Dave, 2014, Viral warfare! Front-line defence and arming the immune system against cancer using oncolytic vaccinia and other viruses, Surgeon., 12, 210, 10.1016/j.surge.2014.01.001 Adair, 2012, Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients, Sci. Transl. Med., 4, 138ra77, 10.1126/scitranslmed.3003578 Jonker, 2018, A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial, Clin. Colorectal Cancer, 17, 231, 10.1016/j.clcc.2018.03.001 Sze, 2012, Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography, Hum. Gene Ther., 23, 91, 10.1089/hum.2011.141 Kim, 2021, Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity, Mol. Cancer Ther., 20, 173, 10.1158/1535-7163.MCT-20-0405 Edukulla, 2009, Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses, Cancer Res., 69, 1448, 10.1158/0008-5472.CAN-08-1160 Nair, 2021, Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade, JCI Insight, 6, 10.1172/jci.insight.144619 Bartlett, 2013, Oncolytic viruses as therapeutic cancer vaccines, Mol. Cancer, 12, 103, 10.1186/1476-4598-12-103 Heiniö, 2020, TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling, Cells, 9, 10.3390/cells9040798 Minev, 2019, First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells, J. Transl. Med., 17, 271, 10.1186/s12967-019-2011-3 Guo, 2013, Life after death: targeting high mobility group box 1 in emergent cancer therapies, Am. J. Cancer Res., 3, 1 Delpeut, 2017, Measles Virus Enters Breast and Colon Cancer Cell Lines through a PVRL4-Mediated Macropinocytosis Pathway, J. Virol., 91, 10.1128/JVI.02191-16 Geoffroy, 2020, The pros and cons of interferons for oncolytic virotherapy, Cytokine Growth Factor Rev., 56, 49, 10.1016/j.cytogfr.2020.07.002 Ebrahimi, 2017, Interferon-Mediated Tumor Resistance to Oncolytic Virotherapy, J. Cell. Biochem., 118, 1994, 10.1002/jcb.25917 Li, 2022, The gamble between oncolytic virus therapy and IFN, Front. Immunol., 13 Tsun, 2016, Oncolytic Immunotherapy for Treatment of Cancer, Adv. Exp. Med. Biol., 909, 241, 10.1007/978-94-017-7555-7_5 Huang, 2021, Species-Specific Deamidation of RIG-I Reveals Collaborative Action between Viral and Cellular Deamidases in HSV-1 Lytic Replication, mBio, 12, 10.1128/mBio.00115-21 Komatsu, 2016, IRF1 Downregulation by Ras/MEK Is Independent of Translational Control of IRF1 mRNA, PLoS One, 11, 10.1371/journal.pone.0160529 Danziger, 2018, Interleukin-6 and Interferon-α Signaling via JAK1-STAT Differentially Regulate Oncolytic versus Cytoprotective Antiviral States, Front. Immunol., 9, 94, 10.3389/fimmu.2018.00094 Glorioso, 2021, Oncolytic HSV Vectors and Anti-Tumor Immunity, Curr. Issues Mol. Biol., 41, 381, 10.21775/cimb.041.381 Walton, 2018, Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells, J. Virol., 92, 10.1128/JVI.00879-18 Lipatova, 2021, Multi-Omics Analysis of Glioblastoma Cells' Sensitivity to Oncolytic Viruses, Cancers (Basel), 13, 10.3390/cancers13215268 Linder, 2021, Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis Virus in a Replication Dependent Manner, Front. Immunol., 12, 10.3389/fimmu.2021.595390 Struzik, 2018, NF-κB Signaling in Targeting Tumor Cells by Oncolytic Viruses-Therapeutic Perspectives, Cancers (Basel), 10, 10.3390/cancers10110426 Arwert, 2020, STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy, Nat. Cell Biol., 22, 758, 10.1038/s41556-020-0527-7 Ottolino-Perry, 2015, Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer, Mol. Oncol., 9, 1539, 10.1016/j.molonc.2015.04.009 Means, 2020, The Propagation and Quantification of Two Emerging Oncolytic Viruses: Vesicular Stomatitis (VSV) and Zika (ZIKV), Methods Mol. Biol., 2097, 253, 10.1007/978-1-0716-0203-4_16 Velazquez-Salinas, 2017, Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV, Hum. Gene Ther. Clin. Dev., 28, 108, 10.1089/humc.2017.015 Stewart, 2021, The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma, Cancers (Basel), 13, 10.3390/cancers13225687 Sun, 2019, Recombinant Oncolytic Vaccinia Viruses Expressing Human β-Defensin 2 Enhance Anti-tumor Immunity, Mol. Ther. Oncolytics, 13, 49, 10.1016/j.omto.2019.03.010 Panagioti, 2021, Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy, J. Clin. Invest., 131, 10.1172/JCI141614 Wang, 2022, NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors, Transl. Res., 240, 64, 10.1016/j.trsl.2021.10.006 Fox, 2019, Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus, Viruses, 11, 10.3390/v11050431 Inoue, 2021, Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing, Mol. Cancer Ther., 20, 1481, 10.1158/1535-7163.MCT-20-0863 Robinson, 2017, Potential and clinical translation of oncolytic measles viruses, Expert Opin. Biol. Ther., 17, 353, 10.1080/14712598.2017.1288713 Bah, 2020, Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients, Mol. Cancer Ther., 19, 2057, 10.1158/1535-7163.MCT-20-0134 Antoszczyk, 2016, Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors, Expert Opin. Orphan Drugs, 4, 129, 10.1517/21678707.2016.1128322 Urbiola, 2018, Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer, Int. J. Cancer, 143, 1786, 10.1002/ijc.31556 Ayala Breton, 2015, Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity, Mol. Ther. Oncolytics, 2, 10.1038/mto.2015.12 Gautam, 2022, Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP, Front. Bioeng. Biotechnol., 10, 10.3389/fbioe.2022.992069 Shi, 2018, Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints, Int. J. Mol. Sci., 19, 10.3390/ijms19051389 Bartee, 2017, Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy, Cancer Res., 77, 2952, 10.1158/0008-5472.CAN-16-1638 Rojas, 2015, Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy, Clin. Cancer Res., 21, 5543, 10.1158/1078-0432.CCR-14-2009 Ott, 2013, CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients, Clin. Cancer Res., 19, 5300, 10.1158/1078-0432.CCR-13-0143 Belkaid, 2013, Effector and memory T cell responses to commensal bacteria, Trends Immunol., 34, 299, 10.1016/j.it.2013.03.003 Viaud, 2013, The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide, Science, 342, 971, 10.1126/science.1240537 Lamas, 2016, CARD9 affects colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands, Nat. Med., 22, 598, 10.1038/nm.4102 Ishino, 2021, Oncolytic Virus Therapy with HSV-1 for Hematological Malignancies, Mol. Ther., 29, 762, 10.1016/j.ymthe.2020.09.041 Watanabe, 2018, Oncolytic Virotherapy by HSV, Adv. Exp. Med. Biol., 1045, 63, 10.1007/978-981-10-7230-7_4 Delwar, 2018, Oncolytic Virotherapy Blockade by Microglia and Macrophages Requires STATone-third, Cancer Res., 78, 718, 10.1158/0008-5472.CAN-17-0599 Hu, 2018, Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer, Cell Death Dis., 9, 274, 10.1038/s41419-018-0325-3 Li, 2020, The Role of Interleukins in Colorectal Cancer, Int. J. Biol. Sci., 16, 2323, 10.7150/ijbs.46651 Kasprzak, 2021, The Role of Tumor Microenvironment Cells in Colorectal Cancer (CRC) Cachexia, Int. J. Mol. Sci., 22, 10.3390/ijms22041565 Sharma, 2023, Inflammasome signaling in colorectal cancer, Transl. Res., 252, 45, 10.1016/j.trsl.2022.09.002 Li, 2023, New insights on IL-36 in intestinal inflammation and colorectal cancer (Review), Exp. Ther. Med., 25, 275, 10.3892/etm.2023.11974 Xu, 2022, The role of IL-36 subfamily in intestinal disease, Biochem. Soc. Trans., 50, 223, 10.1042/BST20211264 Heys, 1994, Interleukin 2 treatment in colorectal cancer: current results and future prospects, Eur. J. Surg. Oncol., 20, 622 Song, 2021, Possible Roles of Interleukin-4 and -13 and Their Receptors in Gastric and Colon Cancer, Int. J. Mol. Sci., 22 Zarogoulidis, 2014, Interleukin-7 and interleukin-15 for cancer, J. Cancer, 5, 765, 10.7150/jca.10471 Conciatori, 2019, Colorectal cancer stem cells properties and features: evidence of interleukin-8 involvement, Cancer Drug Resist., 2, 968 Taniguchi, 2014, IL-6 and related cytokines as the critical lynchpins between inflammation and cancer, Semin. Immunol., 26, 54, 10.1016/j.smim.2014.01.001 Engel, 2010, Anticancer properties of the IL-12 family--focus on colorectal cancer, Curr. Med. Chem., 17, 3303, 10.2174/092986710793176366 Neurath, 2019, IL-23 in inflammatory bowel diseases and colon cancer, Cytokine Growth Factor Rev., 45, 1, 10.1016/j.cytogfr.2018.12.002 Landskron, 2014, Chronic inflammation and cytokines in the tumor microenvironment, J. Immunol. Res., 2014 Wei, 2020, IL-10 and IL-22 in Mucosal Immunity: Driving Protection and Pathology, Front. Immunol., 11, 1315, 10.3389/fimmu.2020.01315 Niess, 2018, The Interleukin-20 Cytokines in Intestinal Diseases, Front. Immunol., 9, 1373, 10.3389/fimmu.2018.01373 Hurtado, 2018, Roles for Interleukin 17 and Adaptive Immunity in Pathogenesis of Colorectal Cancer, Gastroenterology, 155, 1706, 10.1053/j.gastro.2018.08.056 Wu, 2013, Interleukin-17: a promoter in colorectal cancer progression, Clin. Dev. Immunol., 2013, 10.1155/2013/436307 Jou, 2022, Emerging roles for IL-25 and IL-33 in colorectal cancer tumorigenesis, Front. Immunol., 13, 10.3389/fimmu.2022.981479 Aliper, 2014, A role for G-CSF and GM-CSF in nonmyeloid cancers, Cancer Med., 3, 737, 10.1002/cam4.239 Maryam, 2023, Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring, J. Clin. Med., 12 Lee, 2022, Inflammatory Cytokine: An Attractive Target for Cancer Treatment, Biomedicines, 10, 10.3390/biomedicines10092116